EGFR and non-small cell lung carcinoma: The ADAURA study,28 which was the first to investigate a third-generation EGFR-TKI in the adjuvant setting, showed remarkable preliminary DFS improvement in patients with stage IB-IIIA EGFR-mutant NSCLC (HR [osimertinib vs. placebo], 0.20; 95% CI, 0.14–0.30; p < 0.001).29 Given that our previous analysis of the CTONG 1104 study22 indicated a unique spatial–temporal treatment failure pattern with increased intracranial metastasis, it is possible that postoperative osimertinib could significantly lower the incidence of intracranial lesions, resulting in DFS improvement.